After failed repeal of Obamacare in 2017 and again in 2018, the ACA may very well be here to stay. Cost savings on drugs and product growth will have to come from new areas of drug discovery and product launches. Pharmaceutical company’s hiring pace picked up along with the economy and the stock market. In… Read more »
By second quarter 2017 fears of what the new President would do to the health care industry had calmed down. No change in the ACA seemed to be imminent and the President had backed off any conversation about drug pricing. Pharmaceutical companies hiring pace picked up along with the economy and the stock market. 2018… Read more »